(Reuters) – U.S. medical device maker Medtronic (NYSE:MDT) has offered concessions in a bid to secure European Union regulatory approval for its $43 billion acquisition of Covidien (NYSE:COV), the European Commission said.
The takeover will put Medtronic on about the same footing as global leader Johnson & Johnson (NYSE:JNJ) and reduce its overall global tax burden, although it has said the takeover is not an "inversion" deal for tax reasons.
Medtronic submitted concessions last Friday, the EU antitrust authority said. The Commission, which did not provide details in line with its policy, will decide by Nov. 28 whether to clear the deal.
Earlier this month, Covidien said it would sell its Stellarex drug-eluting balloon platform in order to win U.S. approval for the deal.
Medtronic, which makes heart devices, spinal implants, insulin pumps and other products, expects to close the deal in early 2015.